June 24, 2024, Cambridge, MA — Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of John Maraganore, Ph.D., as a Strategic Advisor and Board Observer.

Dr. Maraganore brings a wealth of experience and knowledge in the field of RNA therapeutics. He is known for his remarkable contributions while serving as the founding CEO of Alnylam from 2002 to 2021. At Alnylam, Dr. Maraganore led the company from early platform research on RNA interference through clinical development to global approval and commercialization of the first RNAi therapeutic medicines including, ONPATTRO®, GIVLAARI®, OXLUMO®, LEQVIO® and AMVUTTRA®. His leadership has been instrumental in changing the genetic medicine landscape with groundbreaking RNAi-based therapeutics that are helping patients today.

Daniel Fischer, Co-Founder and CEO of Tevard Biosciences, said, “Dr. Maraganore’s experience and proven track record in the field of RNA interference will be invaluable to Tevard as we advance our initial tRNA-based programs in epilepsies and cardiology through IND-enabling studies and into the clinic. In addition, his insights will help guide the expansion of our innovative tRNA platforms as we continue to develop new therapies for patients with genetic diseases. His deep understanding of the biotechnology industry and his demonstrated commitment to patients aligns perfectly with our mission and values.”

Tevard Biosciences is a pioneer of biotechnological innovation, working tirelessly to unlock the potential of tRNA-based therapies. The company’s initial programs are based on its novel Suppressor tRNA technology platform that uses a viral vector to insert the normal amino acid at the site of the premature stop codon, which occurs within the normal coding sequence due to a mutation. Tevard is focused on neurological disorders, heart disease, and muscular dystrophies, and includes an ongoing research collaboration with Vertex Pharmaceuticals Incorporated to create new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD).

Dr. Maraganore said, “I am honored to be a Strategic Advisor to Tevard, a company at the forefront of developing tRNA-based therapeutics. I was drawn to Tevard’s novel approach of applying tRNAs to restore normal protein function with the potential to address multiple mutations and rare genetic diseases with a single therapy. I look forward to contributing to the success of Tevard and to helping the company realize its vision to cure genetic diseases.”

Dr. Maraganore currently serves as a Venture Partner at ARCH Venture Partners and Atlas Ventures, a Senior Advisor at Blackstone Life Sciences and is principal of JMM Innovation LLC. He previously served as Chair of the Biotechnology Innovation Organization (BIO) and currently serves on the Board of several public and private companies.

For more information about Tevard Biosciences, its research, and its ongoing commitment to curing a broad range of genetic diseases, visit tevard.com.

About Tevard Biosciences

Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The privately held biotechnology company was founded by renown scientists along with life science executives and entrepreneurs who are also fathers of children with Dravet Syndrome, a rare genetic disease. Tevard is advancing the use of its novel Suppressor tRNA platform in neurological disorders, heart disease, and muscular dystrophies. The company has an ongoing research collaboration with Vertex Pharmaceuticals Incorporated aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD). For more information, please visit www.tevard.com.


Tevard Biosciences
Rebecca Zacks